Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LFMD Stock Forecast 2025-2026
$3.64
Current Price
$175.21M
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LFMD Price Targets
+312.1%
To High Target of $15.00
+133.5%
To Median Target of $8.50
+64.8%
To Low Target of $6.00
LFMD Price Momentum
+2.2%
1 Week Change
-30.5%
1 Month Change
-38.3%
1 Year Change
-26.5%
Year-to-Date Change
-77.0%
From 52W High of $15.84
+6.1%
From 52W Low of $3.43
📊 TOP ANALYST CALLS
Did LFMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LifeMD is one of their latest high-conviction picks.
Latest LFMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, LFMD has a bullish consensus with a median price target of $8.50 (ranging from $6.00 to $15.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $3.64, the median forecast implies a 133.5% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sarah James at Cantor Fitzgerald, projecting a 312.1% upside. Conversely, the most conservative target is provided by Steven Valiquette at Mizuho, suggesting a 64.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFMD Analyst Ratings
7
Buy
1
Hold
0
Sell
LFMD Price Target Range
Low
$6.00
Average
$8.50
High
$15.00
Current: $3.64
Latest LFMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 19, 2025 | Keybanc | Steve Dechert | Overweight | Maintains | $8.00 |
| Nov 19, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $9.00 |
| Nov 19, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $6.00 |
| Nov 18, 2025 | B. Riley Securities | William Woods | Buy | Maintains | $10.00 |
| Nov 18, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $8.00 |
| Nov 18, 2025 | BTIG | David Larsen | Buy | Maintains | $10.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $13.00 |
| Aug 6, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $14.00 |
| Aug 6, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $12.00 |
| Jul 14, 2025 | Keybanc | Aleksey Yefremov | Overweight | Maintains | $14.00 |
| Jul 10, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $18.00 |
| Apr 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $14.00 |
| Mar 11, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
| Dec 10, 2024 | Lake Street | Buy | Initiates | $N/A | |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $7.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
LifeMD Inc. (LFMD) Competitors
The following stocks are similar to LifeMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LifeMD Inc. (LFMD) Financial Data
LifeMD Inc. has a market capitalization of $175.21M with a P/E ratio of -6.9x. The company generates $250.09M in trailing twelve-month revenue with a -3.2% profit margin.
Revenue growth is +13.0% quarter-over-quarter, while maintaining an operating margin of -3.3% and return on equity of +543.5%.
Valuation Metrics
Market Cap
$175.21M
Enterprise Value
$153.27M
P/E Ratio
-6.9x
PEG Ratio
0.2x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+13.0%
Gross Margin
+87.7%
Operating Margin
-3.3%
Net Margin
-3.2%
EPS Growth
+12.7%
Financial Health
Cash/Price Ratio
+13.6%
Current Ratio
0.7x
Debt/Equity
193.7x
ROE
+543.5%
ROA
-2.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
LifeMD Inc. (LFMD) Business Model
About LifeMD Inc.
What They Do
Direct-to-patient healthcare and pharmaceutical services.
Business Model
LifeMD operates a direct-to-consumer model, leveraging telehealth technology and online platforms to provide medical consultations, prescription medications, and wellness products. This allows the company to generate revenue through service fees and sales of healthcare products, capitalizing on the growing demand for accessible and affordable healthcare solutions.
Additional Information
The company is positioned to address key challenges in traditional healthcare, such as accessibility and cost, making it a significant player in the expanding telehealth market. By focusing on underserved populations, LifeMD is part of a larger trend towards digital transformation in healthcare.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
304
CEO
Mr. Justin Schreiber
Country
United States
IPO Year
2021
Website
lifemd.comLifeMD Inc. (LFMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.
Dec 03, 2025
By Debanjana Dey
Analyst Blog
Latest News
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026
15 days ago
Quick Summary
LifeMD, Inc. (Nasdaq: LFMD) was recognized on the 2025 Deloitte Technology Fast 500™ and TIME's America's Growth Leaders of 2026 for its revenue growth and leadership in health tech.
Why It Matters
Recognition on prestigious lists highlights LifeMD's robust growth and stability, signaling strong potential for future performance and investor confidence in the health tech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TDOC and LFMD are experiencing differing trajectories in the rising telehealth market, influenced by their fundamentals and growth strategies.
Why It Matters
Differing growth trajectories and fundamentals for TDOC and LFMD indicate varying investment risks and opportunities in the rising telehealth market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LifeMD Inc. (NASDAQ: LFMD) shares declined following the release of its Q3 earnings report, which missed analyst expectations for both revenue and earnings.
Why It Matters
LifeMD Inc.'s earnings miss signals potential operational challenges, possibly leading to decreased investor confidence and a negative impact on stock performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
LifeMD, Inc. (LFMD) reported a quarterly loss of $0.10 per share, worse than the estimated loss of $0.06, compared to a loss of $0.14 per share a year earlier.
Why It Matters
LifeMD's larger-than-expected quarterly loss and year-over-year deterioration may raise concerns about its financial health and growth prospects, potentially impacting investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
LifeMD, Inc. (LFMD) will hold its Q3 2025 earnings call on November 17, 2025, at 4:30 PM EST, featuring CEO Justin Schreiber and CFO Marc Benathen.
Why It Matters
The upcoming Q3 2025 earnings call for LifeMD, Inc. will provide key insights into the company's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
LifeMD has expanded access to Wegovy and Ozempic, offering them at the lowest cash-pay prices, emphasizing patient affordability and quality care.
Why It Matters
LifeMD's expansion of affordable access to Wegovy and Ozempic can drive patient growth, potentially boosting revenue and market share in the competitive telehealth and weight loss sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LFMD Stock
What is LifeMD Inc.'s (LFMD) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, LifeMD Inc. (LFMD) has a median price target of $8.50. The highest price target is $15.00 and the lowest is $6.00.
Is LFMD stock a good investment in 2026?
According to current analyst ratings, LFMD has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LFMD stock?
Wall Street analysts predict LFMD stock could reach $8.50 in the next 12 months. This represents a 133.5% increase from the current price of $3.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LifeMD Inc.'s business model?
LifeMD operates a direct-to-consumer model, leveraging telehealth technology and online platforms to provide medical consultations, prescription medications, and wellness products. This allows the company to generate revenue through service fees and sales of healthcare products, capitalizing on the growing demand for accessible and affordable healthcare solutions.
What is the highest forecasted price for LFMD LifeMD Inc.?
The highest price target for LFMD is $15.00 from Sarah James at Cantor Fitzgerald, which represents a 312.1% increase from the current price of $3.64.
What is the lowest forecasted price for LFMD LifeMD Inc.?
The lowest price target for LFMD is $6.00 from Steven Valiquette at Mizuho, which represents a 64.8% increase from the current price of $3.64.
What is the overall LFMD consensus from analysts for LifeMD Inc.?
The overall analyst consensus for LFMD is bullish. Out of 11 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are LFMD stock price projections?
Stock price projections, including those for LifeMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 4:13 AM UTC